Studies on mechanism of thermal crystal transformation of sitafloxacin hydrates through melting and recrystallization, yielding different anhydrates depending on initial crystalline forms

International Journal of Pharmaceutics

Volumn 402, Issue 1-2, 2010, Pages 110-116

  Suzuki, Tetsuya ^a,b   Araki, Tetsuya ^a   Kitaoka, Hiroaki ^a   Terada, Katsuhide ^a  

^a DAIICHI SANKYO CO   (Japan)

^b TOHO UNIVERSITY   (Japan)

Author keywords

Crystal transformation; Crystallographic analysis; Protonation; Thermal properties; Torsion at quinolone ring

Indexed keywords

AMINE; AMPHOLYTE; CARBOXYL GROUP; QUINOLONE; SITAFLOXACIN;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; INFRARED SPECTROSCOPY; IONIZATION; MELTING POINT; PRIORITY JOURNAL; THERMAL ANALYSIS; TORSION; WATER VAPOR; X RAY DIFFRACTION;

ANTI-BACTERIAL AGENTS; CRYSTALLIZATION; DIFFERENTIAL THERMAL ANALYSIS; FLUOROQUINOLONES; FREEZING; SPECTROPHOTOMETRY, INFRARED; STEAM; TEMPERATURE; X-RAY DIFFRACTION;

EID: 78349311035     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.09.034     Document Type: Article

References (14)

1. Haleblian J., McCrone W. Pharmaceutical applications of polymorphism. J. Pharm. Sci. 1969, 58:911-929.
2. Hu T.C., Wang S.L., Chen T.F., Lin S.Y. Hydration-induced proton transfer in the solid state of norfloxaci. J. Pharm. Sci. 2002, 91:1351-1357.
3. Ito S., Nishimura M., Kobayashi Y., Itai S., Yamamoto K. Characterization of polymorphs and hydrates of GK-128, a serotonin3 receptor antagonist. Int. J. Pharm. 1997, 151:133-143.
4. Jasti R.B., Du J., Vasavada C.R. Characterization of thermal behavior of etoposide. Int. J. Pharm. 1995, 118:161-167.
5. Kaneniwa N., Yamaguchi T., Watari N., Otsuka M. Hygroscopicity of carbamazepine crystalline powders. Yakugaku Zasshi (Japanese) 1984, 104:184-190.
6. Kojima T., Onoue S., Katoh F., Teraoka R., Matsuda Y., Kitagawa S., Mitsutomo T. Effect of spectroscopic properties on photostability of tamoxifen citrate polymorphs. Int. J. Pharm. 2007, 336:346-351.
7. Kojima T., Kato F., Teraoka R., Matsuda Y., Kitagawa S., Mitsutomo T. Physicochemical characterization of tamoxifen citrate pseudopolymorphs, methanolate and ethanolate. Chem. Pharm. Bull. 2007, 55:407-411.
8. Okuda J., Rumamurthy T., Yamasaki S. The potent antibacterial activity of sitafloxacin against fluoroquinolone-resistant clinical isolates of Vibrio cholerae O1. Microbiol. Immunol. 2007, 51:467-469.
9. Rocco L.W., Morphet C., Laughlin M.S. Solid-state characterization of zanoterone. Int. J. Pharm. 1995, 122:17-25.
10. Sato K., Hoshino K., Tanaka M., Hayakawa I., Osada Y. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob. Agents Chemother. 1992, 36:1491-1498.
11. Suzuki T., Kitaoka H., Miwa Y., Taga T. Crystal structure of 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid (Sitafloxacin) sesquihydrate. Anal. Sci. 2000, 16:343-344.
12. Touyama M., Higa F., Nakasone C., Shinzato T., Akamine M., Haranaga S., Tateyaka M., Nakasone I., Yamane N., Fujita J. In vitro activity of sitafloxacin against clinical strains of Streptocossus pneumoniae with defined amino acid substitutions in QRDR of gyrase A and topoisomerase IV. J. Antimacrob. Chemother. 2006, 58:1279-1282.
13. Turel I., Leban I., Bukovec N. Crystal structure and characterization of bismuth(III) compound with quinolone family member (ciprofloxacin). Antibacterial study. J. Inorg. Biochem. 1997, 66:241-245.
14. Yamazaki K., Suzuki M. Crystal structure of 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid. Anal. Sci. 1998, 14:463-464.